珂立苏治疗新生儿呼吸窘迫综合征68例疗效观察  

作　　者：翟敏[1] 李晓玲[1] 宋双生 廖延彦 吴海燕[1] 李先清[1] 吴静静[1] 靳新红[1] 兰安云[1] 郑福平[1] 黄传云 吴维平[1] 吴海丽[1] 

机构地区：[1]湖北省枣阳市第一人民医院新生儿科,湖北襄阳441200

出　　处：《中国药业》2015年第B12期14-16,共3页China Pharmaceuticals

摘　　要：目的观察珂立苏治疗新生儿呼吸窘迫综合征的疗效。方法收集医院新生儿病房2010年10月至2014年1月使用珂立苏治疗新生儿呼吸窘迫综合征患儿68例，总结患儿一般情况，比较用药前后患儿生命特征及血气分析结果的差异，并与既往传统给养方式死亡率比较。结果新生儿呼吸窘迫综合征多见于男孩，早产儿特别是小于32周的早产儿和剖宫产分娩儿；珂立苏用药后患儿呼吸、心率、血氧分压、血二氧化碳分压明显改善；与既往传统给养方式比较，死亡率明显下降。结论珂立苏治疗新生儿呼吸窘迫综合症疗效明显。Objective To summarize the curative effect of Kelisu in treatment of neonatal respiratory distress syndrome.Method To collect using Calsurf in treatment of neonatal respiratory distress syndrome 68 cases of neonatal ward in the first hospital of Zaoyang from 2010 October to 2014 January and sum up the children with neonatal respiratory distress syndrome in general.Dif- ferences were compared before and after treatment with R,HR,PCO2,PO2.Results The occurrence of neonatal respiratory distress syndrome patients were more common in boys, especially in preterm infants less than 32 weeks premature and cesarean delivery infants children ;Calsurf before and after treatment with R, HR,PCO2,PO2 improved significantly ;compared with the previous traditional ways of oxygen, mortality rates dropped significantly.Conclusion Kelisu in treatment of neonatal respiratory distress syndrome curative effect.

关 键 词：肺透明膜病 珂立苏 疗效观察 

分 类 号：R969.4[医药卫生—药理学] R977.6[医药卫生—药学]